Posts

COVID-19’s Effect on Pharmaceutical R&D Funding

The COVID-19 pandemic has had a significant impact on research and development (R&D) budgets for pharmaceutical companies. Many companies have prioritized the development of...

Quantum computing has the potential to revolutionize the field of genomic analysis

Quantum computing has the potential to revolutionize the field of genomic analysis by enabling researchers to analyze and understand genetic data in ways that...

HPC is playing a crucial role in powering genomic big data

Genomic data, which includes the genetic information of an organism, has the potential to revolutionize many fields, including medicine, agriculture, and environmental science. However,...

Chemopreventive effects and anti-tumorigenic mechanisms of Actinidia arguta

Actinidia arguta, also known as Sarunashi, is a fruit commonly grown in Japan's Okayama Prefecture. Researchers from Okayama University, led by Sakae Arimoto-Kobayashi, have...

AI and HPC are revolutionizing drug discovery

Artificial intelligence (AI) and high performance computing (HPC) have revolutionized the field of drug discovery by significantly speeding up the process and increasing its...

The global market for biosimilars is expected to witness significant growth in the coming years

The global market for biosimilars is expected to witness significant growth in the coming years. According to a report by MarketsandMarkets, the market is...

Extracellular Vesicles May Improve Immunotherapy

A new study by researchers at Karolinska Institutet (KI) demonstrates how extracellular vesicles (EVs) activate the immune system in mice and seem to make...

Meenta and Agilent Technologies Partnership

Delivering value and speed for genomics researchers

Artemis supercomputer is looking to unlock a deeper understanding of genomics

Atemis can deliver a total of 7.2 petaflos of double-precision HPL performance and run workloads 120x faster than their previous system.

Unlocking the Potential of AI-Driven Small Molecule Drug Discovery

Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the closing of a $60 million Series A financing to advance its novel tNova platform and deliver therapies to patients faster than ever before.